RECURRENT LUNG SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control OngoingThis study tests whether adding veliparib (a PARP inhibitor) to the chemotherapy drug temozolomide helps people with small cell lung cancer that has come back or stopped responding to treatment. About 97 participants will receive either the combo or a placebo plus temozolomide. T…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for lung cancer patients: experimental combo targets hard-to-treat tumors
Disease control OngoingThis early-phase trial tests a three-drug combination (tazemetostat, topotecan, and pembrolizumab) in adults with small cell lung cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors. About…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo aims to outsmart Chemo-Resistant lung cancer
Disease control OngoingThis study tests whether adding berzosertib to standard chemotherapy (topotecan) helps people with relapsed small cell lung cancer live longer without their cancer growing. About 104 participants will receive either the combo or topotecan alone. The goal is to see if blocking the…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC